Insider · CIK 0001589725
Helen M. Thackray
officer
Files at BCRX (BIOCRYST PHARMACEUTICALS INC). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 31, 2025 | BCRX BIOCRYST PHARMACEUTICALS INC | FTax withholding Common Stock | -7,525 | $7.50 | $56k | 377,318 | Apr 2, 2025 |
| Dec 19, 2024 | BCRX BIOCRYST PHARMACEUTICALS INC | AGrant or award Common Stock | +125,950 | $0.00 | $0 | 390,939 | Dec 23, 2024 |
| Dec 19, 2024 | BCRX BIOCRYST PHARMACEUTICALS INC | FTax withholding Common Stock | -6,096 | $7.39 | $45k | 384,843 | Dec 23, 2024 |
| Dec 19, 2024 | BCRX BIOCRYST PHARMACEUTICALS INC | AGrant or award Emp. Stock Option (Right to Buy)derivative | +260,950 | $0.00 | $0 | 260,950 | Dec 23, 2024 |
| Dec 14, 2024 | BCRX BIOCRYST PHARMACEUTICALS INC | FTax withholding Common Stock | -7,150 | $7.53 | $54k | 264,989 | Dec 17, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.